15 May 2025
💊Medicare Drug Price Negotiation Program Draft Guidance Overview
Medicare Program; Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Request
Summary
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' draft guidance for the third cycle of the Medicare Drug Price Negotiation Program, the first cycle of renegotiation, and manufacturer effectuation of the maximum fair price for 2026, 2027, and 2028 for the implementation of the Inflation Reduction Act (IRA).
Agencies
- Health and Human Services Department
- Centers for Medicare & Medicaid Services
Business Impact
$$$ - High
The draft guidance establishes the framework for the Medicare Drug Price Negotiation Program, which directly affects drug pricing strategies for manufacturers, impacting their financial operations. Compliance with the outlined provisions for maximum fair prices will be necessary for affected businesses.